NBTXR 3

Drug Profile

NBTXR 3

Alternative Names: Hafnium Oxide nanoparticles; NBTX 3; NBTXR-3; PEP-503

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanobiotix
  • Developer Nanobiotix; PharmaEngine
  • Class Antineoplastics; Radiosensitisers
  • Mechanism of Action Free radical stimulants; Radiography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase II/III Soft tissue sarcoma
  • Phase I/II Head and neck cancer; Prostate cancer; Rectal cancer
  • Preclinical Hepatocellular carcinoma; Solid tumours

Most Recent Events

  • 09 Nov 2017 IND approval for phase I trial in Head and neck and Lung cancer expected in 1H 2018
  • 31 Oct 2017 Nanobiotix plans a clinical trial for Cancer (Combination therapy) in USA
  • 23 Oct 2017 NanoBiotix completes patient enrolment in a phase II/III trial in Soft tissue sarcoma in Australia, Belgium, France, Germany, Hong Kong, Hungary, Italy, Norway, the Philippines, Poland, Romania, South Africa and Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top